

10826836

=> d his

(FILE 'HOME' ENTERED AT 11:48:09 ON 06 JUN 2005)

FILE 'REGISTRY' ENTERED AT 11:48:19 ON 06 JUN 2005

L1 STRUCTURE UPLOADED
L2 33 S L1
L3 STRUCTURE UPLOADED
L4 16 S L3
L5 290 S L4 SSS FULL


FILE 'CAPLUS' ENTERED AT 11:51:13 ON 06 JUN 2005

L6 23 S L5

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l4

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:end

=> d his

(FILE 'HOME' ENTERED AT 11:48:09 ON 06 JUN 2005)


FILE 'REGISTRY' ENTERED AT 11:48:19 ON 06 JUN 2005

L1 STRUCTURE UPLOADED
L2 33 S L1
L3 STRUCTURE UPLOADED
L4 16 S L3
L5 290 S L4 SSS FULL

10826836


FILE 'CAPLUS' ENTERED AT 11:51:13 ON 06 JUN 2005
L6 23 S L5

=> d 11
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 13
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 1-23 bib abs hitstr

L6 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:394803 CAPLUS
 DN 142:423819
 TI Neutrophil activation by immune response modifier compounds
 IN Tomai, Mark A.; Vasilakos, John P.; Wightman, Paul D.
 PA 3M Innovative Properties Company, USA
 SO U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005096259	A1	20050505	US 2004-978850	20041101
	WO 2005041891	A2	20050512	WO 2004-US36351	20041101
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,				
	SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,				
	NE, SN, TD, TG				
PRAI	US 2003-516116P	P	20031031		
	US 2003-517805P	P	20031106		

AB The invention provides a method of activating neutrophils. Generally, the method includes contacting neutrophils with a neutrophil-activating IRM compound and/or a TLR8-selective agonist in an amount effective to activate the neutrophils. In some embodiments, the method may be used to treat a condition treatable by activating neutrophils. In another aspect, the invention provides pharmaceutical compns. that generally include a neutrophil-activating IRM compound and/or a TLR8-selective agonist, or a pharmaceutically acceptable form thereof, in an amount effective to activate neutrophils.


IT 313357-78-7 532959-63-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (neutrophil activation by immune response modifier compds.)

RN 313357-78-7 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]- (9CI) (CA INDEX NAME)

10826836



RN 532959-63-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:316318 CAPLUS

DN 142:392406

TI Preparation of alkoxy substituted imidazoquinolines as immunomodulators

IN Lindstrom, Kyle J.; Merrill, Bryon A.; Haraldson, Chad A.; Rice, Michael J.; Kshirsagar, Tushar A.; Heppner, Philip D.; Wurst, Joshua R.; Niwas, Shri; Johannessen, Sarah C.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 386 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005032484	A2	20050414	WO 2004-US32616	20041001
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				


EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

PRAI US 2003-508634P

P

20031003

GI



AB The title imidazoquinolines with an alkoxy substituent at the 6-, 7-, 8- or 9-position [I; R = alkyl, alkoxy, OH, etc.; n = 0-1; R¹, R² = H, non-interfering substituents; R³ = ZYR⁴, ZHet, etc. (Z = alkylene, alkenylene, and alkynylene optionally interrupted with one or more O groups; Y = S, SO, SO₂, (un)substituted SO₂NH, etc.; R⁴ = H, alkyl, aryl, etc.; Het = (un)substituted heterocyclyl)], useful as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic (no specific biol. data given), were prepared E.g., a multi-step synthesis of II, was given. Pharmaceutical compns. containing the compds. I are disclosed.

IT 850057-42-0P 850057-43-1P 850057-44-2P


850057-45-3P 850064-17-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of alkoxy substituted imidazoquinolines as immunomodulators)

RN 850057-42-0 CAPLUS


CN Methanesulfonamide, N-[[5-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]pentyl]methyl]- (9CI) (CA INDEX NAME)



10826836


RN 850057-43-1 CAPLUS

CN Acetamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]- (9CI) (CA INDEX NAME)



RN 850057-44-2 CAPLUS


CN Methanesulfonamide, N-[[5-[[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]oxy]pentyl]methyl]- (9CI) (CA INDEX NAME)



RN 850057-45-3 CAPLUS


CN Acetamide, N-[6-[[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]- (9CI) (CA INDEX NAME)

10826836



RN 850064-17-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-[3-(2-oxo-1-pyrrolidinyl)propoxy]-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



IT 812631-90-6P 850069-14-6P 850069-15-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of alkoxy substituted imidazoquinolines as immunomodulators)

RN 812631-90-6 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)

10826836




RN 850069-14-6 CAPLUS

CN Carbamic acid, [6-[[4-amino-1-[4-[(methanesulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 850069-15-7 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-[(6-aminohexyl)oxy]-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:220136 CAPLUS
 DN 142:273998
 TI Treatment for CD5+ B cell lymphoma
 IN Miller, Richard L.; Spaner, David E.
 PA 3M Innovative Properties Company, USA
 SO U.S. Pat. Appl. Publ., 25 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005054665	A1	20050310	US 2004-933594	20040903
	WO 2005023190	A2	20050317	WO 2004-US28688	20040903
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				

PRAI US 2003-500478P P 20030905
 US 2004-561440P P 20040412


AB The present invention provides methods for increasing expression of cell surface mols. of CD5+ B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5+ B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response modifier compds. to a subject in need of such treatment. Suitable immune response modifier compds. include agonists of TLR7 and/or TLR8. A 5 % 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine cream was applied once per day to a lymphomatous skin deposit associated with chronic lymphocytic leukemia of a 71-yr old man diagnosed with Rai Stage 0 CLL. The lesion disappeared after six weeks of treatment and had not recurred by three months after treatment ceased.

IT 532959-63-0

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (immune response modifiers for increasing expression of cell surface mols. and treatment of CD5-pos. B cell lymphoma)

RN 532959-63-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:216680 CAPLUS
 DN 142:298105
 TI Preparation of aryloxy and arylalkyleneoxy substituted imidazoquinolines
 as inducers of cytokine biosynthesis for treatment of viral and neoplastic
 disease
 IN Lindstrom, Kyle J.; Martin, Hugues; Merrill, Bryon A.; Rice, Michael J.;
 Wurst, Joshua R.; Haraldson, Chad A.; Kshirsagar, Tushar; Heppner, Philip
 D.; Niwas, Shri; Griesgraber, George W.; Radmer, Matthew R.
 PA 3M Innovative Properties Company, USA
 SO PCT Int. Appl., 291 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005020999	A1	20050310	WO 2004-US28021	20040827
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-498270P	P	20030827		
	US 2004-581254P	P	20040618		
OS	MARPAT 142:298105				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. [I; R3 = (un)substituted alk(en/yn)ylene-hetero/aryl,
 alk(en/yn)ylene-hetero/arylene-SO-R4, alk(en/yn)ylene-hetero/arylene-
 alkylene-SO-R4, etc.; R4 = H, (un)substituted alk(en/yn)yl, hetero/aryl,

heterocyclyl, etc.; R = alkyl, OH and derivs., halo, CF₃; R', R'' = independently H, non-interfering substituent; n = 0-1; and their pharmaceutically acceptable salts], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. For example, II was prepared via cyclocondensation 7-Benzoyloxy-N'-(2-methylpropyl)quinoline-3,4-diamine (preparation given) with tri-Me orthobutyrate, followed by oxidation and amination. Thus, I induced interferon and tumor necrosis factor in human cells (no data).

IT **847575-05-7P**, N-[2-[4-Amino-2-(ethoxymethyl)-7-hydroxy-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide
847575-61-5P, N-[4-(4-Amino-7-benzyloxy-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide **847576-00-5P**,
 N-[2-[4-Amino-8-benzyloxy-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide **847577-50-8P**,
 N-[2-[4-Amino-7-(benzyloxy)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (immunomodulator; preparation of aryloxy and arylalkyleneoxy imidazoquinolines as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease).

RN 847575-05-7 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-hydroxy-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 847575-61-5 CAPLUS



CN Methanesulfonamide, N-[4-[4-amino-2-ethyl-7-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)

10826836




RN 847576-00-5 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-8-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 847577-50-8 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)




IT **847575-03-5P**, N-[4-[4-Amino-7-benzyloxy-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]methanesulfonamide **847575-34-2P**, N-[4-[4-Amino-8-(benzyloxy)-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]methanesulfonamide **847575-41-1P**, N-[4-[4-Amino-8-(benzyloxy)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]methanesulfonamide **847575-43-3P**, N-[4-[4-Amino-8-(benzyloxy)-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]methanesulfonamide **847575-44-4P**, N-[4-[4-Amino-8-(benzyloxy)-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]methanesulfonamide **847575-49-9P**, N-[4-(4-Amino-2-butyl-8-hydroxy-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide **847575-58-0P**, N-[4-(4-Amino-2-ethyl-8-hydroxy-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide **847575-62-6P**, N-[4-(4-Amino-2-ethyl-7-hydroxy-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide **847575-79-5P**, N-[2-[4-Amino-2-(ethoxymethyl)-7-(3-methoxybenzyloxy)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide **847575-80-8P**, N-[2-[4-Amino-7-(2-chlorobenzyloxy)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide **847575-81-9P**, N-[2-[4-Amino-2-(ethoxymethyl)-7-(4-fluorobenzyloxy)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide **847575-82-0P**, N-[2-[4-Amino-2-(ethoxymethyl)-7-(3-methylbenzyloxy)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide **847575-83-1P**, N-[2-[4-Amino-7-[(benzothiazol-2-yl)methoxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide **847575-84-2P**, N-[2-[4-Amino-2-(ethoxymethyl)-7-(5-trifluoromethylfuran-2-ylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide **847575-85-3P**, Ethyl 5-[[[4-Amino-2-(ethoxymethyl)-1-[2-[(methylsulfonyl)amino]-2-methylpropyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]methyl]furan-2-carboxylate **847576-01-6P**, N-[2-[4-Amino-2-(ethoxymethyl)-8-hydroxy-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide **847577-07-5P 847577-09-7P 847577-13-3P 847577-15-5P 847577-23-5P 847577-51-9P**, N-[2-[4-Amino-2-(ethoxymethyl)-7-[3-(thien-2-yl)propoxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(immunomodulator; preparation of aryloxy and arylalkyleneoxy imidazoquinolines as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)


RN 847575-03-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-7-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 847575-34-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-butyl-8-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RN 847575-41-1 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-8-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



10826836


RN 847575-43-3 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-methyl-8-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 847575-44-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-ethyl-8-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RN 847575-49-9 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-2-butyl-8-hydroxy-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



10826836


RN 847575-58-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-8-hydroxy-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 847575-62-6 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-7-hydroxy-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 847575-79-5 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-[(3-methoxyphenyl)methoxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)

10826836



RN 847575-80-8 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-7-[(2-chlorophenyl)methoxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI)
(CA INDEX NAME)



RN 847575-81-9 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-[(4-fluorophenyl)methoxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI)
(CA INDEX NAME)

10826836




RN 847575-82-0 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-[(3-methylphenyl)methoxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)




RN 847575-83-1 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-7-(2-benzothiazolylmethoxy)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 847575-84-2 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-[[5-(trifluoromethyl)-2-furanyl]methoxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 847575-85-3 CAPLUS



CN 2-Furan carboxylic acid, 5-[[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

10826836



RN 847576-01-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-8-hydroxy-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 847577-07-5 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-[[[(methylamino)carbonyl]amino]methyl]-7-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 847577-06-4

CMF C23 H27 N7 O4 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 847577-09-7 CAPLUS

CN Ethanesulfonamide, N-[2-[4-amino-2-[[[(methylamino)carbonyl]amino]methyl]-7-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 847577-08-6

CMF C24 H29 N7 O4 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 847577-13-3 CAPLUS

CN 1-Butanesulfonamide, N-[2-[4-amino-2-[[[(methylamino)carbonyl]amino]methyl]-7-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 847577-12-2


CMF C26 H33 N7 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 847577-15-5 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-[[[(methylamino)carbonyl]amino]methyl]-


10826836

7-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-1,1,1-trifluoro-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 847577-14-4


CMF C23 H24 F3 N7 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 847577-23-5 CAPLUS


CN Benzenemethanesulfonamide, N-[2-[4-amino-2-[[[(methylamino)carbonyl]amino]methyl]-7-(phenylmethoxy)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 847577-22-4

CMF C29 H31 N7 O4 S


10826836



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 847577-51-9 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-[3-(2-thienyl)propoxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI)
(CA INDEX NAME)



IT **847578-88-5P**, N-[2-[4-Amino-2-(ethoxymethyl)-7-(prop-2-ynyloxy)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide
847578-89-6P, N-[2-[4-Amino-2-(ethoxymethyl)-7-[[3-(thien-2-

10826836


yl)prop-2-ynyl]oxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aryloxy and arylalkyleneoxy imidazoquinolines as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)


RN 847578-88-5 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-(2-propynyloxy)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 847578-89-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-[[3-(2-thienyl)-2-propynyl]oxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10826836

L6 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:216676 CAPLUS
DN 142:291342
TI Methods related to the treatment of mucosal associated conditions
IN Miller, Richard L.; Ma, David Q.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005020995	A1	20050310	WO 2004-US28407	20040901
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-499607P	P	20030902		
AB	Using interrupted delivery of Immune Response Modifiers (IRMs) by intermittently applying an IRM to a mucosal surface it is possible to achieve therapeutic levels and durations of cytokine induction, while substantially reducing irritation side effects.				
IT	313357-84-5 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods for treatment of mucosal associated conditions)				
RN	313357-84-5 CAPLUS				
CN	Methanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)				



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:160991 CAPLUS
 DN 142:246181
 TI Formulations containing an amine-based immune response modifier
 IN Hammerbeck, David M.; Guy, Cynthia A.; Leung, Suzanne S.
 PA 3M Innovative Properties Company, USA
 SO PCT Int. Appl., 118 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016275	A2	20050224	WO 2004-US25277	20040805
	WO 2005016275	A3	20050414		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005070460	A1	20050331	US 2004-911800	20040805
PRAI	US 2003-493109P	P	20030805		


AB Pharmaceutical formulations in an aqueous (preferably, sprayable) formulation including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolophthyridine amines, thiazolophthyridine amines, and 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, are provided. In one embodiment, the aqueous formulations are advantageous for treatment and/or prevention of allergic rhinitis, viral infections, sinusitis, and asthma. For example, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide (IRM 1) was prepared as a 0.375% aqueous solution capable of being nasally administered via

a spray pump. The solution contained IRM 1 0.375%, CM-cellulose sodium 0.1%, benzalkonium chloride 0.02%, disodium EDTA 0.1%, L-lactic acid 1.53%, PEG 400 15%, 1N NaOH as needed for pH 4.0, and water to 100%. The IRM 1 solution (50 µL) administered to rats once 4 h before infection with humanized, non-lethal influenza virus, almost completely suppressed the virus. titer.

IT 313356-36-4 532959-63-0 642473-39-0
 642473-59-4 642473-62-9 642473-65-2
 740809-55-6 740809-59-0 845638-55-3
 845638-56-4 845638-57-5 845638-61-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (solns. containing amine-based immunomodulators)
 RN 313356-36-4 CAPLUS
 CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-


10826836

yl)ethyl]- (9CI) (CA INDEX NAME)




RN 532959-63-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 642473-39-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 642473-59-4 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-


10826836

c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 642473-62-9 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 642473-65-2 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-(cyclopropylmethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



10826836


RN 740809-55-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 740809-59-0 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 845638-55-3 CAPLUS


CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)

10826836



RN 845638-56-4 CAPLUS


CN Methanesulfonamide, N-[[5-[[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-(methanesulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-6-yl]oxy]pentyl]methyl]- (9CI) (CA INDEX NAME)



RN 845638-57-5 CAPLUS


CN Acetamide, N-[[6-[[[4-amino-2-(ethoxymethyl)-1-[2-(methanesulfonylamino)hexyl]oxy]hexyl]-1H-imidazo[4,5-c]quinolin-6-yl]oxy]hexyl]- (9CI) (CA INDEX NAME)

10826836



RN 845638-61-1 CAPLUS

CN Methanesulfonamide, N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:158509 CAPLUS

DN 142:233285

TI Infection prophylaxis using immune response modifier compounds

IN Hammerbeck, David M.; Guy, Cynthia A.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016273	A2	20050224	WO 2004-US25241	20040805
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

US 2005070460 A1 20050331 US 2004-911800 20040805

PRAI US 2003-493109P P 20030805


AB The present invention provides methods of providing prophylaxis to a subject against an infectious agent. In general, the methods include topically administering to the respiratory tract of a subject an immune response modifier (IRM) compound in an amount effective to reduce infection by the agent. Rats treated with IRM compound, N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide, four hours before or twenty-four hours before and four hours before intranasal infection with humanized, nonlethal influenza virus showed reduced viral titers in nasal lavage fluid and whole lung homogenates.

IT 642473-62-9

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (infection prophylaxis using immune response modifier compds.)

RN 642473-62-9 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:29289 CAPLUS

DN 142:134599

TI Preparation of sulfonamide substituted imidazoquinolines as immunomodulators

IN Griesgraber, George W.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.


KIND

DATE


APPLICATION NO.

DATE

PI WO 2005003065 A2 20050113 WO 2004-US20607 20040625
 WO 2005003065 A3 20050310
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 PRAI US 2003-483200P P 20030627
 OS MARPAT 142:134599
 GI



I



II

AB The title imidazoquinoline and tetrahydroimidazoquinoline compds. I [R1 = alkyl-NR3-SO2-X-R4, alkenyl-NR3-SO2-X-R4, alkyl-NR6-SO2-R7; X = a bond, NR5; R4 = (un)substituted aryl, heteroaryl, heterocyclyl, alkyl, alkenyl; R2 = H, alkyl, alkenyl, aryl, etc.; R3 = H, alkyl; R5 = H, alkyl; or R4 and R5 can combine to form (un)substituted 3-7 membered heterocyclic ring; R6 = H, alkyl; R7 = H, alkyl; R6 and R7 combine to form (un)substituted heterocyclic ring; n = 0-4; R = alkyl, alkoxy, halo, CF3] that contain sulfonamide functionality at the 1-position are useful as immune response modifiers. Thus, reacting 1-(3-aminopropyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine with methanesulfonic anhydride in the presence of Et3N in MeCN afforded II. The title compds. I were tested for interferon α and TNF α induction in human cells (data given for over 30 compds.). The compds. and compns. of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT 313356-36-4P 532959-63-0P 534568-90-6P
 642473-39-0P 642473-41-4P 642473-42-5P
 642473-44-7P 642473-49-2P 642473-53-8P
 642473-54-9P 642473-56-1P 642473-57-2P
 642473-58-3P 642473-59-4P 642473-62-9P
 642473-63-0P 642473-65-2P 823809-06-9P
 823809-07-0P 823809-08-1P 823809-12-7P


10826836

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonamide substituted imidazoquinolines as immunomodulators)


RN 313356-36-4 CAPLUS

CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 532959-63-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 534568-90-6 CAPLUS


CN Methanesulfonamide, N-[3-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]- (9CI) (CA INDEX NAME)

CN1C=NC2=C1C(=C3C(=C2)N(C)C(=O)S(=O)(=O)C)C=C3N

CN Methanesulfonamide, N-[4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




CN Methanesulfonamide, N-[4-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




CN Methanesulfonamide, N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]- (9CI). (CA INDEX NAME)

10826836




RN 642473-44-7 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-hexyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 642473-49-2 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-2-pentyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 642473-53-8 CAPLUS


10826836

CN Methanesulfonamide, N-[3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)




RN 642473-54-9 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)



RN 642473-56-1 CAPLUS


CN Methanesulfonamide, N-[3-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)



10826836


RN 642473-57-2 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)



RN 642473-58-3 CAPLUS


CN Methanesulfonamide, N-[3-[4-amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)



RN 642473-59-4 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)

10826836




RN 642473-62-9 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 642473-63-0 CAPLUS


CN Ethanesulfonamide, N-[4-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



10826836


RN 642473-65-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(cyclopropylmethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 823809-06-9 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)



RN 823809-07-0 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-2-pentyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



10826836

RN 823809-08-1 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 823809-12-7 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:29288 CAPLUS

DN 142:114068

TI Preparation of sulfonamide substituted imidazoquinolines as immunomodulators

IN Lindstrom, Kyle J.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 58 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005003064	A2	20050113	WO 2004-US20606	20040625
	WO 2005003064	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, EY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-483200P	P	20030627		
OS	MARPAT 142:114068				
GI					



AB The title 1-imidazoquinoline and tetrahydroimidazoquinoline compds. I [R1 = alkyl-NR3-SO2-X-R4, alkenyl-NR3-SO2-X-R4, alkyl-NR6-SO2-R7; X = a bond, NR5; R4 = (un)substituted aryl, heteroaryl, heterocyclyl, alkyl, alkenyl; R2 = H, alkyl, alkenyl, aryl, etc.; R3 = H, alkyl; R5 = H, alkyl; or R4 and R5 can combine to form (un)substituted 3-7 membered heterocyclic ring; R6 = H, alkyl; R7 = H, alkyl; R6 and R7 combine to form (un)substituted heterocyclic ring; n = 0-4; R = alkyl, alkoxy, halo, CF3] that contain sulfonamide functionality at the 1-position are useful as immune response modifiers. E.g., a multi-step synthesis of II, starting from tert-Bu 4-(2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butylcarbamate, was given. The title compds. I were tested for interferon α and TNF α induction in human cells (data given for over 30 compds.). The compds. and compns. of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT 313356-36-4P 532959-63-0P 534568-90-6P
 642473-39-0P 642473-41-4P 642473-42-5P
 642473-44-7P 642473-49-2P 642473-53-8P
 642473-54-9P 642473-56-1P 642473-57-2P
 642473-58-3P 642473-59-4P 642473-62-9P
 642473-63-0P 642473-65-2P 823809-06-9P
 823809-07-0P 823809-08-1P 823809-12-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


10826836

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonamide substituted imidazoquinolines as immunomodulators)


RN 313356-36-4 CAPLUS

CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 532959-63-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 534568-90-6 CAPLUS


CN Methanesulfonamide, N-[3-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]- (9CI) (CA INDEX NAME)



10826836


RN 642473-39-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 642473-41-4 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 642473-42-5 CAPLUS


CN Methanesulfonamide, N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]- (9CI) (CA INDEX NAME)



10826836


RN 642473-44-7 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-hexyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 642473-49-2 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-2-pentyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 642473-53-8 CAPLUS


CN Methanesulfonamide, N-[3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)

10826836




RN 642473-54-9 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)



RN 642473-56-1 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)




RN 642473-57-2 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro-1H-


10826836

imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)




RN 642473-58-3 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)




RN 642473-59-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 642473-62-9 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 642473-63-0 CAPLUS


CN Ethanesulfonamide, N-[4-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 642473-65-2 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-(cyclopropylmethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)

10826836




RN 823809-06-9 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)



RN 823809-07-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-2-pentyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 823809-08-1 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10826836


NAME)



● HCl

RN 823809-12-7 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:1126841 CAPLUS

DN 142:79920

TI Delivery of immune response modifier compounds

IN Wightman, Paul D.; Zarraga, Isidro Angelo E.; Jing, Naiyong; Liu, Jie J.

PA USA

SO U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 640,904.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004258698	A1	20041223	US 2004-821335	20040409
	US 2004091491	A1	20040513	US 2003-640904	20030814
	WO 2004091500	A2	20041028	WO 2004-US11062	20040409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


WO 2004108072 A2 20041216 WO 2004-US11081 20040409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-462140P P 20030410
 US 2003-640904 A2 20030814
 US 2003-515256P P 20031029
 US 2004-545424P P 20040218
 US 2004-545542P P 20040218
 US 2002-403846P P 20020815

GI



I


- AB The present invention provides immune response modifiers (IRMs) associated with (typically, attached to, and preferably, covalently attached to) macromol. support materials. The IRM compds. in such IRM-support complexes retain biol. activity. Such attachment of an IRM to a macromol. support material provides for the localized biol. activity of the IRM. The IRM I was prepared and IRMs were linked to such carriers as avidin beads, gold particles, silica nanoparticles, and polymers.
- IT **812631-90-6P 812631-99-5P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(delivery of immune response modifier compds.)


RN 812631-90-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 812631-99-5 CAPLUS

CN Carbamic acid, [6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:905622 CAPLUS

DN 141:374755

TI Compositions and methods for induction of opioid receptors, and therapeutic use

IN Birmachu, Woubalem M. R.; Slade, Herbert B.; Stolpa, John C.; Urosevic, Mirjana

10826836

PA 3M Innovative Properties Company, USA
 SO U.S. Pat. Appl. Publ., 16 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004214851	A1	20041028	US 2004-832737	20040427
	WO 2004096144	A2	20041111	WO 2004-US12897	20040427
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-466227P P 20030428


AB The invention provides compns. and method for increasing expression of opioid receptors. Generally, the compns. include an opioid receptor-inducing compound (e.g. an imidazoquinoline amine compound) and, optionally, an opioid receptor ligand. Generally, the methods include contacting a cell with an amount of an opioid receptor-inducing compound effective for inducing expression of the opioid receptor and, optionally, contacting the cell with an opioid receptor ligand. The methods of the invention may be used e.g. to reduce the effects of tissue damage.

IT 313355-91-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. and methods for induction of opioid receptors, and therapeutic use)

RN 313355-91-8 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:802451 CAPLUS
 DN 141:289086
 TI Selective activation of cellular activities mediated through a common
 TOLL-like receptor
 IN Fink, Jason R.; Gupta, Shalley K.
 PA 3M Innovative Properties Company, USA
 SO U.S. Pat. Appl. Publ., 14 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004191833	A1	20040930	US 2004-807934	20040324
	WO 2004087049	A2	20041014	WO 2004-US8979	20040324
	WO 2004087049	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG

PRAI US 2003-457336P P 20030325

AB Methods of identifying compds. that selectively modulate cellular
 activities mediated by a common TLR are provided. Generally, the methods
 include providing an assay to detect modulation of a first cellular
 activity mediated by a TLR; providing an assay to detect modulation of a
 second cellular activity mediated by the TLR; performing each assay using
 a test compound; and identifying the test compound as a compound that
 selectively modulates at least one cellular activity of a plurality of
 activities mediated by a common TLR if the test compound modulates the first
 cellular activity to a different extent than it modulates the second
 TLR-mediated cellular activity. Compds. identified by such methods,
 pharmaceutical compns. including such compds., and methods of treating a
 condition by administering such pharmaceutical compns. to a subject are
 also provided.

IT 642473-49-2 750595-95-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(selective activation of cellular activities mediated through common
 TOLL-like receptor)

RN 642473-49-2 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-2-pentyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)

10826836



RN 750595-95-0 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:722830 CAPLUS

DN 141:236623

TI Selective modulation of TLR-mediated biological activity

IN Fink, Jason R.; Gorden, Keith B.; Gorski, Kevin S.; Gupta, Shalley K.; Qiu, Xiaohong; Vasilakos, John P.

PA 3M Innovative Properties Company, USA

SO U.S. Pat. Appl. Publ., 22 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171086	A1	20040902	US 2004-788731	20040227
	WO 2004075865	A2	20040910	WO 2004-US6115	20040227
	WO 2004075865	A3	20041118		
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,				

IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC,
 LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,
 MZ, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-450484P P 20030227

AB Methods of identifying a compound that selectively modulates at least one TLR-mediated cellular activity are disclosed. Generally, the methods include identifying a compound as a compound that selectively modulates at least one TLR-mediated cellular activity if the compound modulates one TLR-mediated cellular activity to a different extent than it modulates a second TLR-mediated cellular activity. Compds. so identified and pharmaceutical compns. including such compds. are also disclosed. Methods of selectively modulating immune cells and methods of treating certain conditions are also provided. Such methods include administering to cells or a subject a compound that selectively modulates a TLR-mediated cellular activity.


IT 313356-02-4 532959-63-0 750595-95-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(selective modulation of TLR-mediated biol. activity)

RN 313356-02-4 CAPLUS


CN 1-Propanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 532959-63-0 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)

10826836



RN 750595-95-0 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:681403 CAPLUS

DN 141:185096

TI Methods and compositions related to IRM compounds and toll-like receptor 8

IN Gorden, Keith B.; Qiu, Xiaohong; Vasilakos, John P.

PA 3M Innovative Properties Company, USA

SO U.S. Pat. Appl. Publ., 25 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004162309	A1	20040819	US 2004-777310	20040212
	WO 2004071459	A2	20040826	WO 2004-US4353	20040212
	WO 2004071459	A3	20050127		
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,				

MZ, MZ, NA, NI
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-447179P P 20030213


AB Methods of eliciting a toll-like receptor 8 (TLR8)-mediated cellular response are disclosed. Such methods include administration of either a TLR8 agonist or a TLR8 antagonist to an IRM (immune response modifier)-responsive cell so that the IRM compound affects at least one TLR8-mediate cellular signaling pathway. In some cases, the method may provide prophylactic or therapeutic treatment for a condition treatable by modulating a TLR8-mediated cellular pathway.

IT 313356-02-4 313356-36-4 532959-63-0
 642473-42-5 642473-62-9 740809-55-6
 740809-56-7 740809-58-9 740809-59-0
 740809-60-3 740809-61-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods and comps. related to immune response modifier compds. and affecting toll-like receptor 8-mediated cellular response for therapeutic treatments)


RN 313356-02-4 CAPLUS

CN 1-Propanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 313356-36-4 CAPLUS


CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]- (9CI) (CA INDEX NAME)



10826836


RN 532959-63-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 642473-42-5 CAPLUS

CN Methanesulfonamide, N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 642473-62-9 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 740809-55-6 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 740809-56-7 CAPLUS


CN Methanesulfonamide, N-[2-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)

10826836



RN 740809-58-9 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 740809-59-0 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)

10826836




RN 740809-60-3 CAPLUS

CN Methanesulfonamide, N-[2-(4-amino-2-butyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 740809-61-4 CAPLUS

CN Methanesulfonamide, N-[2-(4-amino-2-ethyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:589386 CAPLUS
 DN 141:139130
 TI Vaccines comprising TLR agonist, TNF/TNF receptor agonist and antigen for inducing cellular immune response against infection or tumor
 IN Noelle, Randolph J.; Ahonen, Cory L.; Kedl, Ross M.
 PA 3M Innovative Properties Company, USA
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004060319	A2	20040722	WO 2003-US41796	20031230
	WO 2004060319	A3	20041104		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004141950	A1	20040722	US 2003-748010	20031230
PRAI	US 2002-437398P	P	20021230		


AB The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist, a TNF or TNF receptor agonist and an tumor antigen or viral, bacterial or parasitic antigen. The TLR agonist is an agonist of TLR1-10 e.g. IRM compound, MALP-2, LPS, polyIC, CpG or any combination. The TNF agonist is an agonist or antibody against CD40L, OX40 ligand, 4-1BB ligand, CD27, CD30 ligand, TNF- α , TNF- β , RANK ligand, LT- α , LT- β , GITR ligand or LIGHT. The TNF receptor agonist is an antibody or agonist of CD40, OX40, 4-1BB, CD27 ligand, CD30, TNFR2, RANK, LT- α R, LT- β R, HVEM, GITR, TROY or RELT. These immunostimulatory combinations are useful for inducing Th1 immune response or antigen-specific CD8+ effector and memory T cell response against infectious and neoplastic conditions.

IT **532959-63-0 642473-39-0**
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vaccines comprising TLR agonist, TNF/TNFR agonist and antigen for inducing cellular immune response against infection or tumor)
 RN 532959-63-0 CAPLUS
 CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 642473-39-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:566606 CAPLUS

DN 141:123628

TI Preparation of aryl/heteroaryl substituted imidazoquinolines as immunomodulators

IN Hays, David S.; Niwas, Shri; Kshirsagar, Tushar; Ghosh, Tarun K.; Gupta, Shalley K.; Heppner, Philip D.; Merrill, Bryon A.; Bonk, Jason D.; Danielson, Michael E.; Gerster, John F.; Haraldson, Chad A.; Johannessen, Sarah C.; Kavanagh, Maureen A.; Lindstrom, Kyle J.; Prince, Ryan B.; Radmer, Matthew R.; Rice, Michael J.; Squire, David J.; Strong, Sarah A.; Wurst, Joshua R.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 465 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058759	A1	20040715	WO 2003-US40373	20031218
	WO 2004058759	C1	20050317		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2004147543 A1 20040729 US 2003-739787 20031218
 PRAI US 2002-435889P P 20021220
 US 2003-516331P P 20031031
 OS MARPAT 141:123628
 GI




- AB Title compds. I (R = alkyl, alkoxy, OH, CF₃; n = 0, 1; R₁, R₂ = H, non-interfering substituent; R₃ = ArZ, aminosulfonylaryl, aminocarbonylaryl, etc.; Ar = aryl, heteroaryl; Z = bond, alkylene, alkenylene, alkynylene) which are immunomodulators, inducing cytokines biosynthesis, and inhibiting tumor necrosis factors biosynthesis, are prepared For example, 2-butyl-1-isobutyl-7-(thiophen-3-yl)-1H-imidazo[4,5-c]quinolin-4-amine was prepared in a multi-step synthesis starting from 3-bromoaniline, tri-Et orthoformate, and Meldrum's acid. I are useful in the treatment of viral and neoplastic diseases.
- IT **723284-27-3P 723284-31-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazoquinoline derivs. as immunomodulators for treatment of viral and antineoplastic diseases)
- RN 723284-27-3 CAPLUS
- CN Methanesulfonamide, N-[4-[4-amino-7-bromo-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)

10826836



RN 723284-31-9 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-7-bromo-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



IT 723265-59-6P 723265-60-9P 723265-62-1P
723268-70-0P 723268-71-1P 723268-82-4P
723269-18-9P 723269-85-0P 723272-09-1P
723272-11-5P 723272-13-7P 723272-16-0P
723272-18-2P 723272-20-6P 723272-22-8P
723272-24-0P 723272-26-2P 723272-28-4P
723272-30-8P 723272-32-0P 723272-34-2P
723272-36-4P 723272-38-6P 723272-40-0P
723272-42-2P 723272-44-4P 723272-46-6P
723272-48-8P 723272-50-2P 723272-52-4P
723272-54-6P 723272-56-8P 723272-58-0P
723272-60-4P 723272-62-6P 723272-64-8P
723272-66-0P 723272-69-3P 723272-73-9P
723275-52-3P 723275-54-5P 723275-56-7P
723275-58-9P 723275-60-3P 723275-62-5P
723275-64-7P 723275-66-9P 723275-68-1P
723275-70-5P 723275-72-7P 723275-74-9P
723275-76-1P 723275-78-3P 723275-80-7P
723275-82-9P 723275-84-1P 723275-86-3P
723275-88-5P 723275-90-9P 723275-92-1P
723278-51-1P 723278-54-4P 723278-56-6P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)

(preparation of imidazoquinoline derivs. as immunomodulators for treatment of viral and antineoplastic diseases)


RN 723265-59-6 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-7-phenyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RN 723265-60-9 CAPLUS


CN Methanesulfonamide, N-[2-(4-amino-7-phenyl-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)



RN 723265-62-1 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-phenyl-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)

10826836




RN 723268-70-0 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(3-pyridinyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RN 723268-71-1 CAPLUS


CN 1-Propanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(3-pyridinyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



10826836


RN 723268-82-4 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-(3-pyridinyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 723269-18-9 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-7-(3-pyridinyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)




RN 723269-85-0 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-butyl-7-[(1E)-2-(3-pyridinyl)ethenyl]-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10826836




RN 723272-09-1 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-phenyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-08-0


CMF C24 H29 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-11-5 CAPLUS


10826836

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(3-methylphenyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-10-4


CMF C25 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-13-7 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(2-methylphenyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-12-6

CMF C25 H31 N5 O3 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-16-0 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(2-hydroxyphenyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 723272-15-9

CMF C24 H29 N5 O4 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-18-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(3-hydroxyphenyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 723272-17-1


CMF C24 H29 N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-20-6 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(4-cyanophenyl)-2-(ethoxymethyl)-1H-


10826836

imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-19-3


CMF C25 H28 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-22-8 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-7-(4-ethenylphenyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-21-7

CMF C26 H31 N5 O3 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-24-0 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(3,5-dimethylphenyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-23-9

CMF C26 H33 N5 O3 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-26-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(4-ethylphenyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-25-1


CMF C26 H33 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-28-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-[5-(hydroxymethyl)-3-


10826836

pyridinyl]-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (salt)
(9CI) (CA INDEX NAME)

CM 1

CRN 723272-27-3


CMF C24 H30 N6 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-30-8 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-[4-(hydroxymethyl)phenyl]-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 723272-29-5

CMF C25 H31 N5 O4 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-32-0 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(4-methoxyphenyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-31-9

CMF C25 H31 N5 O4 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-34-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(2-chlorophenyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-33-1


CMF C24 H28 Cl N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-36-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(3-chlorophenyl)-2-(ethoxymethyl)-1H-


10826836

imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-35-3


CMF C24 H28 Cl N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-38-6 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-7-(2,4-difluorophenyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-37-5

CMF C24 H27 F2 N5 O3 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-40-0 CAPLUS

CN Methanesulfonamide, N-[4-[7-(3-acetylphenyl)-4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-39-7

CMF C26 H31 N5 O4 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-42-2 CAPLUS

CN Methanesulfonamide, N-[4-[7-(4-acetylphenyl)-4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-41-1


CMF C26 H31 N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-44-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(2-ethoxyphenyl)-1H-


10826836

imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-43-3


CMF C26 H33 N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-46-6 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(3-ethoxyphenyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-45-5

CMF C26 H33 N5 O4 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-48-8 CAPLUS

CN Benzamide, 3-[4-amino-2-(ethoxymethyl)-1-[4-[(methylsulfonyl)amino]butyl]-1H-imidazo[4,5-c]quinolin-7-yl]-N-(2-methylpropyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-47-7

CMF C29 H38 N6 O4 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-50-2 CAPLUS

CN Acetamide, N-[2-[4-amino-2-(ethoxymethyl)-1-[4-[(methylsulfonyl)amino]butyl]-1H-imidazo[4,5-c]quinolin-7-yl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-49-9


CMF C26 H32 N6 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-52-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(2-ethoxy-5-


10826836

methylphenyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate
(9CI) (CA INDEX NAME)

CM 1

CRN 723272-51-3


CMF C27 H35 N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-54-6 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-[4-(1-methylethoxy)phenyl]-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-53-5

CMF C27 H35 N5 O4 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-56-8 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(2,4-dimethoxyphenyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-55-7

CMF C26 H33 N5 O5 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-58-0 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(2,6-dimethoxyphenyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-57-9


CMF C26 H33 N5 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-60-4 CAPLUS

CN Benzenepropanoic acid, 4-[4-amino-2-(ethoxymethyl)-1-[4-


10826836

[(methylsulfonyl)amino]butyl]-1H-imidazo[4,5-c]quinolin-7-yl]-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-59-1


CMF C27 H33 N5 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-62-6 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-1-[4-
[(methylsulfonyl)amino]butyl]-1H-imidazo[4,5-c]quinolin-7-yl]phenyl]-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-61-5

CMF C25 H32 N6 O5 S2


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-64-8 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(ethoxymethyl)-1-[4-
[(methylsulfonyl)amino]butyl]-1H-imidazo[4,5-c]quinolin-7-yl]phenyl]-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-63-7

CMF C25 H32 N6 O5 S2




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723272-66-0 CAPLUS

CN Pyrrolidine, 1-[4-[4-amino-2-(ethoxymethyl)-1-[4-[(methylsulfonyl)amino]butyl]-1H-imidazo[4,5-c]quinolin-7-yl]benzoyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-65-9


CMF C29 H36 N6 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-69-3 CAPLUS

CN Benzamide, 4-[4-amino-2-(ethoxymethyl)-1-[4-[(methylsulfonyl)amino]butyl]-


10826836

1H-imidazo[4,5-c]quinolin-7-yl]-N-(2-methylpropyl)-, trifluoroacetate
(9CI) (CA INDEX NAME)

CM 1

CRN 723272-68-2


CMF C29 H38 N6 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723272-73-9 CAPLUS


CN Morpholine, 4-[4-[4-amino-2-(ethoxymethyl)-1-[4-
[(methylsulfonyl)amino]butyl]-1H-imidazo[4,5-c]quinolin-7-yl]benzoyl]-,
trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723272-72-8

CMF C29 H36 N6 O5 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723275-52-3 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-7-phenyl-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-51-2


CMF C24 H29 N5 O2 S



CM 2

10826836


CRN 76-05-1
CMF C2 H F3 O2



RN 723275-54-5 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-2-propyl-7-(3-pyridinyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 723275-53-4
CMF C23 H28 N6 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 723275-56-7 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-2-propyl-7-(4-pyridinyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

10826836

CM 1

CRN 723275-55-6


CMF C23 H28 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723275-58-9 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-7-(3-methylphenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-57-8

CMF C25 H31 N5 O2 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723275-60-3 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(4-methylphenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-59-0

CMF C25 H31 N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723275-62-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(2-methylphenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-61-4


CMF C25 H31 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723275-64-7 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(2-hydroxyphenyl)-2-propyl-1H-


10826836

imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 723275-63-6


CMF C24 H29 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723275-66-9 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-7-(3-cyanophenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-65-8

CMF C25 H28 N6 O2 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723275-68-1 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-[5-(hydroxymethyl)-3-pyridinyl]-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 723275-67-0

CMF C24 H30 N6 O3 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723275-70-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(4-methoxyphenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-69-2


CMF C25 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723275-72-7 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(2-chlorophenyl)-2-propyl-1H-


10826836

imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-71-6


CMF C24 H28 Cl N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723275-74-9 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-7-(3-chlorophenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-73-8

CMF C24 H28 Cl N5 O2 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723275-76-1 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-(4-chlorophenyl)-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-75-0

CMF C24 H28 Cl N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723275-78-3 CAPLUS

CN Benzamide, 3-[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-77-2


CMF C25 H30 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723275-80-7 CAPLUS

CN Benzamide, 3-[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]-N-(2-methylpropyl)-, trifluoroacetate (9CI)


10826836

(CA INDEX NAME)

CM 1

CRN 723275-79-4


CMF C29 H38 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723275-82-9 CAPLUS


752175 02-9 01-103
CN Methanesulfonamide, N-[4-[4-amino-7-[4-(1-methylethoxy)phenyl]-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-81-8

CMF C27 H35 N5 O3 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723275-84-1 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-[3-(aminomethyl)phenyl]-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-83-0

CMF C25 H32 N6 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723275-86-3 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-7-[4-(methanesulfonyl)phenyl]-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-85-2


CMF C25 H31 N5 O4 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723275-88-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-1-[4-[(methanesulfonyl)amino]butyl]-2-


10826836

propyl-1H-imidazo[4,5-c]quinolin-7-yl]phenyl]-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 723275-87-4


CMF C25 H32 N6 O4 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723275-90-9 CAPLUS


CN Pyrrolidine, 1-[4-[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]benzoyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723275-89-6

CMF C29 H36 N6 O3 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723275-92-1 CAPLUS

CN Benzamide, 4-[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]-N-(2-methylpropyl)-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 723275-91-0

CMF C29 H38 N6 O3 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 723278-51-1 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(3-pyridinyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723268-70-0


CMF C23 H28 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723278-54-4 CAPLUS

CN Ethanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(3-pyridinyl)-1H-


10826836

imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723278-53-3


CMF C24 H30 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 723278-56-6 CAPLUS


CN 2-Propanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-7-(3-pyridinyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 723278-55-5

CMF C25 H32 N6 O3 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L6 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:515768 CAPLUS
DN 141:66260
TI Non-NFκB reporter assay for screening effectors (immune response
modifiers) of Toll-like receptor activity using TLR-inducible promoters
IN Gupta, Shalley K.; Ghosh, Tarun K.; Fink, Jason R.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004053452	A2	20040624	WO 2003-US34554	20031031
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				
	GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,				
	LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				
	OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,				
	TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004132079	A1	20040708	US 2003-732563	20031210

PRAI US 2002-432650P P 20021211

AB The present invention provides assays for detecting agonists of Toll-like receptors. The assays may be useful for detecting a broader range of TLR activation than is possible by monitoring NF- κ B activation, and may be used to screen for effectors that do not activate an NF- κ B-dependent pathway. The assays of the present invention also may provide a more relevant indication of the quant. character of a particular cellular response to TLR activation by a particular TLR agonist. The assays include providing a cell culture transfected with a nucleic acid sequence that encodes a reporter operably linked to a TLR-inducible expression control sequence. The assays of the present invention employ a recombinant cell line capable of inducing gene expression from an promoter of a gene that encodes an immune system compound (e.g., IFN- α) in response to TLR activation. The system using a Namalwa cell line as expression host and IFN- α promoter was demonstrated.


IT 313355-91-8

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(IRM, as effector of Toll-like receptor; non-NF κ B reporter assay for screening effectors (immune response modifiers) of Toll-like receptor activity using TLR-inducible promoters)

RN 313355-91-8 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:515636 CAPLUS

DN 141:48572

TI Reporter gene systems to screen for effectors of Toll-like receptors

IN Gupta, Shalley K.; Ghosh, Tarun K.; Fink, Jason R.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004053057	A2	20040624	WO 2003-US34563	20031031
	WO 2004053057	A3	20041028		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004197865 A1 20041007 US 2003-732796 20031210


PRAI US 2002-432651P P 20021211

AB Reporter gene systems that can be used to screen for modulators of Toll-like receptors are described. These systems include an expression cassette for the Toll-like receptor gene and a second cassette for a reporter gene under control of the Toll-like receptor, e.g. from a gene for a cytokine, chemokine, a co-stimulatory mol. or a defensin. The method may be used to screen for effectors that do not activate an NF- κ B-dependent pathway. The system uses an animal cell line, preferably a Namalwa cell, as expression host.

IT **313355-91-8**
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (as effector of Toll-like receptor; reporter gene systems to screen for effectors of Toll-like receptors)

RN 313355-91-8 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:33981 CAPLUS

DN 140:94043

TI Preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis.

IN Griesgraber, George W.

PA 3M Innovative Properties Company, USA


SO U.S., 86 pp., Cont. of U.S. Ser. No. 27,273, abandoned.
 CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6677349	B1	20040113	US 2003-425054	20030428
	US 2004106638	A1	20040603	US 2003-669051	20030923
	US 2004132762	A1	20040708	US 2003-734306	20031212
	US 6888000	B2	20050503		
PRAI	US 2001-27273	B1	20011221		
	US 2003-425054	A1	20030428		
	US 2003-669051	A1	20030923		
OS	MARPAT 140:94043				
GI					



AB Title compds. [I; R1 = alkyl-NR3SO2XR4, alkenyl-NR3SO2XR4; X = bond, R5; R4 = (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl; R2 = H, (substituted) alkyl, alkenyl, aryl, heteroaryl, alkyl-O-alkyl, alkyl-O-alkenyl; R3 = H, alkyl; R5 = H, alkyl; R4R5 = atoms to form a 3-7 membered (substituted) heterocyclyl; n = 0-4; R = alkyl, alkoxy, halo, CF3], were prepared. Thus, a stirred solution of 4-chloro-3-nitroquinoline in CH2Cl2 was treated with Et3N and 1,2-diamino-2-methylpropane to give 2-methyl-N1-(3-nitroquinolin-4-yl)propane-1,2-diamine. A solution of the latter in THF was cooled to 0° and treated with a 1 N NaOH solution of di-tert-Bu dicarbonate under rapid stirring followed by warming to ambient temperature and stirring overnight; addnl. di-tert-Bu dicarbonate was added and stirring was continued for 3 d. to give tert-Bu 1,1-dimethyl-2-[(3-nitroquinolin-4-yl)amino]ethylcarbamate. This in PhMe was treated with Pt/C and shaken under H2 for 6 h to give tert-Bu 2-(3-aminoquinolin-4-yl)-1,1-dimethylethylcarbamate. The aminoquinoline in CH2Cl2 was cooled to 0° and treated with Et3N and ethoxyacetyl chloride to give a syrup which was refluxed overnight with Et3N in EtOH to give tert-Bu 2-[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate. The imidazoquinoline in CH2Cl2 was treated with 3-chloroperoxybenzoic acid and stirred 2 h to give tert-Bu 2-[2-(ethoxymethyl)-5-oxido-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate. The latter in 1,2-dichloroethane was heated to 70° and treated with concentrated NH4OH; p-toluenesulfonyl chloride was added and the reaction mixture was heated in a sealed tube for 2 h to give tert-Bu 2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethylcarbamate. This was refluxed in EtOH containing HCl for 2 h to give 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine. 1-(2-Amino-2-methylpropyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine in CH2Cl2 at 0° was treated with Et3N and MeSO2Cl and the reaction was allowed to warm to ambient temperature overnight to give N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-

dimethylethyl]methanesulfonamide (claimed compound). I induced interferon in an in vitro human blood cell system at lowest effective concns. of 0.0001-10 μ M.


IT 313355-89-4P 313355-91-8P 313355-97-4P
 313355-98-5P 313356-01-3P 313356-03-5P
 313356-05-7P 313356-25-1P 313356-27-3P
 313356-36-4P 313356-37-5P 313356-39-7P
 313356-40-0P 313356-44-4P 313356-63-7P
 313356-65-9P 313356-67-1P 313356-71-7P
 313356-72-8P 313356-74-0P 313356-76-2P
 313356-98-8P 313357-00-5P 313357-09-4P
 313357-11-8P 313357-13-0P 313357-15-2P
 313357-29-8P 313357-43-6P 313357-84-5P
 313357-85-6P 313357-90-3P 313357-95-8P
 313357-97-0P 313357-99-2P 313358-02-0P
 313358-51-9P 313359-06-7P 313359-52-3P
 313359-79-4P 313359-81-8P 313359-85-2P
 313359-89-6P 313359-91-0P 313359-93-2P
 313359-97-6P 532959-63-0P 534568-90-6P
 642473-06-1P 642473-21-0P 642473-23-2P
 642473-39-0P 642473-41-4P 642473-42-5P
 642473-44-7P 642473-49-2P 642473-53-8P
 642473-54-9P 642473-56-1P 642473-57-2P
 642473-58-3P 642473-59-4P 642473-62-9P
 642473-63-0P 642473-65-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazoquinolinesulfonamides as inducers of cytokine biosynthesis)

RN 313355-89-4 CAPLUS


CN Benzenemethanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 313355-91-8 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)

10826836




RN 313355-97-4 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-[(4-methoxyphenyl)methyl]-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RN 313355-98-5 CAPLUS


CN 1-Butanesulfonamide, N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 313356-01-3 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-phenyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)


10826836



RN 313356-03-5 CAPLUS
CN 1-Propanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
CM 1
CRN 313356-02-4
CMF C19 H27 N5 O2 S



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 313356-05-7 CAPLUS
CN 1-Octanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

10826836

CM 1

CRN 313356-04-6


CMF C24 H37 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-25-1 CAPLUS

CN Benzenemethanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-24-0

CMF C23 H27 N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-27-3 CAPLUS

CN Ethenesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-26-2


CMF C24 H27 N5 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 313356-36-4 CAPLUS

CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]- (9CI) (CA INDEX NAME)


10826836



RN 313356-37-5 CAPLUS
CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 313356-36-4
CMF C17 H23 N5 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 313356-39-7 CAPLUS
CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-1,1,1-trifluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


10826836

CRN 313356-38-6
CMF C17 H20 F3 N5 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 313356-40-0 CAPLUS
CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313355-91-8
CMF C19 H27 N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-44-4 CAPLUS

CN 2-Propanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-43-3


CMF C21 H31 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313356-63-7 CAPLUS


10826836

CN Benzenemethanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313355-89-4


CMF C25 H31 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313356-65-9 CAPLUS


CN Ethenesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-64-8

CMF C26 H31 N5 O2 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-67-1 CAPLUS

CN 1-Propanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-66-0


CMF C21 H31 N5 O2 S



CM 2

10826836


CRN 76-05-1
CMF C2 H F3 O2



RN 313356-71-7 CAPLUS
CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-1,1,1-trifluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 313356-70-6
CMF C19 H24 F3 N5 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 313356-72-8 CAPLUS
CN 1-Propanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)


10826836



RN 313356-74-0 CAPLUS
CN 2-Propanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 313356-76-2 CAPLUS
CN 1-Octanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 313356-98-8 CAPLUS
CN Benzenemethanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)

10826836



RN 313357-00-5 CAPLUS

CN Ethenesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 313357-09-4 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-08-3

CMF C15 H23 N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313357-11-8 CAPLUS

CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-7,7-dimethyl-2-oxo-, (1S,4R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-10-7

CMF C28 H39 N5 O3 S




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10826836



RN 313357-13-0 CAPLUS
CN 1-Butanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 313357-12-9
CMF C22 H33 N5 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 313357-15-2 CAPLUS
CN 1-Hexadecanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-14-1
CMF C34 H57 N5 O2 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313357-29-8 CAPLUS

CN 1-Propanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-3-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-28-7

CMF C21 H30 Cl N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313357-43-6 CAPLUS

CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-7,7-dimethyl-2-oxo-, (1R,4S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-42-5

CMF C28 H39 N5 O3 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10826836



RN 313357-84-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 313357-85-6 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-84-5

CMF C18 H25 N5 O3 S




CM 2

CRN 76-05-1

10826836

CMF C2 H F3 O2




RN 313357-90-3 CAPLUS

CN Benzenemethanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-89-0


CMF C24 H29 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313357-95-8 CAPLUS

CN Ethanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


10826836

CRN 313357-94-7
CMF C19 H27 N5 O3 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 313357-97-0 CAPLUS
CN 1-Propanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-96-9
CMF C20 H29 N5 O3 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313357-99-2 CAPLUS

CN 1-Butanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-98-1


CMF C21 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313358-02-0 CAPLUS


10826836

CN 1-Propanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-3-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313358-01-9


CMF C20 H28 Cl N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313358-51-9 CAPLUS


CN Benzenemethanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-2-nitro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313358-50-8

CMF C24 H28 N6 O5 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313359-06-7 CAPLUS


CN 1-Octanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-05-6

CMF C25 H39 N5 O3 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313359-52-3 CAPLUS

CN 1-Dodecanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-51-2


CMF C29 H47 N5 O3 S




CM 2

10826836


CRN 76-05-1
CMF C2 H F3 O2



RN 313359-79-4 CAPLUS
CN Methanesulfonamide, N-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 313359-81-8 CAPLUS
CN 2-Propanesulfonamide, N-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 313359-85-2 CAPLUS
CN Benzenemethanesulfonamide, N-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)

10826836




RN 313359-89-6 CAPLUS

CN Ethanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RN 313359-91-0 CAPLUS


CN 1-Propanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RN 313359-93-2 CAPLUS


10826836

CN 1-Butanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 313359-97-6 CAPLUS

CN Benzenemethanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RN 532959-63-0 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



10826836

RN 534568-90-6 CAPLUS

CN Methanesulfonamide, N-[3-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 642473-06-1 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 642473-05-0


CMF C18 H25 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



10826836


RN 642473-21-0 CAPLUS

CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-2-oxo-, (1R,4R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 642473-20-9


CMF C25 H33 N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 642473-23-2 CAPLUS


CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-2-oxo-, (1S,4S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 642473-22-1

10826836


CMF C25 H37 N5 O4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 642473-39-0 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



10826836


RN 642473-41-4 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 642473-42-5 CAPLUS

CN Methanesulfonamide, N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 642473-44-7 CAPLUS


CN Methanesulfonamide, N-[4-(4-amino-2-hexyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



10826836


RN 642473-49-2 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-pentyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 642473-53-8 CAPLUS


CN Methanesulfonamide, N-[3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)



RN 642473-54-9 CAPLUS


CN Methanesulfonamide, N-[3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)

10826836




RN 642473-56-1 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)



RN 642473-57-2 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)




RN 642473-58-3 CAPLUS

CN Methanesulfonamide, N-[3-[4-amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-


10826836

c]quinolin-1-yl]propyl]- (9CI) (CA INDEX NAME)



RN 642473-59-4 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RN 642473-62-9 CAPLUS


CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)

10826836




RN 642473-63-0 CAPLUS

CN Ethanesulfonamide, N-[4-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 642473-65-2 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(cyclopropylmethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



IT 642473-24-3

10826836

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(preparation of imidazoquinolinesulfonamides as inducers of cytokine
biosynthesis)


RN 642473-24-3 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-
imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1

CRN 313360-31-5


CMF C18 H29 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:434369 CAPLUS

DN 139:26620

TI Topical pharmaceuticals comprising an immune response modifier

IN Skwierczynski, Raymond D.; Busch, Terri F.; Gust-Heiting, Amy L.;
Fretland, Mary T.; Scholz, Matthew T.


PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003045391	A1	20030605	WO 2002-US38190	20021127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2467828	AA	20030605	CA 2002-2467828	20021127
	US 2003199538	A1	20031023	US 2002-306019	20021127
	EP 1450804	A1	20040901	EP 2002-798470	20021127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005510540	T2	20050421	JP 2003-546893	20021127
PRAI	US 2001-340605P	P	20011129		
	US 2002-378452P	P	20020506		
	WO 2002-US38190	W	20021127		
OS	MARPAT 139:26620				
GI					




AB Pharmaceutical formulations comprise an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, and other heterocyclic fused ring derivs.; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid are useful for the treatment of dermal associated conditions. Topical formulations containing, e.g., I are provided. In one embodiment, the topical formulations are advantageous for treatment of actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.

IT **534568-83-7 534568-90-6**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical pharmaceuticals comprising an immune response modifier)


RN 534568-83-7 CAPLUS

CN Ethanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 534568-90-6 CAPLUS

CN Methanesulfonamide, N-[3-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:417574 CAPLUS

DN 139:929

TI Toll-like receptor (TLR) pathway-based methods for identification of
immune response modifier (IRM) compounds, and methods of use of such
compounds

IN Gorden, Keith B.; Qiu, Xiaohong; Tomai, Mark A.; Vasilakos, John P.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003043572	A2	20030530	WO 2002-US36758	20021114
	WO 2003043572	A3	20030724		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2004014779 A1 20040122 US 2002-294935 20021114
 EP 1455700 A2 20040915 EP 2002-780689 20021114
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2005513021 T2 20050512 JP 2003-545253 20021114
 PRAI US 2001-332412P P 20011116
 WO 2002-US36758 W 20021114
 AB Methods for identifying a compound that activates a TLR-mediated cellular
 signaling pathway is disclosed. The method includes (a) exposing a
 TLR-pos. cell culture to a test compound and measuring a TLR-mediated
 cellular response; (b) exposing a TLR-neg. cell culture to a test compound
 and measuring a TLR-mediated cellular response; and (c) identifying the
 test compound as an IRM if the cellular response in the TLR-pos. cell
 culture is greater than the cellular response of the TLR-neg. cell
 culture. Methods of eliciting a TLR-mediated cellular response are also
 disclosed. Such methods include administration of an IRM compound to an
 IRM-responsive cell so that the IRM compds. affects at least one
 TLR-mediate cellular signaling pathway.
 IT **313355-91-8 313356-36-4 532959-63-0**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (toll-like receptor pathway-based methods for identification of immune
 response modifier compds., and methods of use of such compds.)
 RN 313355-91-8 CAPLUS
 CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-
 yl)butyl]- (9CI) (CA INDEX NAME)




RN 313356-36-4 CAPLUS
 CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-
 yl)ethyl]- (9CI) (CA INDEX NAME)



RN 532959-63-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:449990 CAPLUS

DN 137:28292

TI Screening method for identifying compounds that selectively induce interferon alpha

IN Tomai, Mark A.; Vasilakos, John P.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002046749	A2	20020613	WO 2001-US46698	20011206
	WO 2002046749	A3	20030828		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,				


GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2430206	AA	20020613	CA 2001-2430206	20011206
AU 2002032498	A5	20020618	AU 2002-32498	20011206
US 2002110840	A1	20020815	US 2001-13193	20011206
EP 1360486	A2	20031112	EP 2001-992019	20011206

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2005500510	T2	20050106	JP 2002-548435	20011206
PRAI US 2000-254229P	P	20001208		
WO 2001-US46698	W	20011206		

GI




AB Methods for screening for compds. that selectively induce IFN- α production and methods for ameliorating conditions in a patient using a small mol. that selectively induces the production of IFN- α are disclosed. Cytokine expression was determined in various cell types (PBMC, CD14+ cells, pDC2-enriched cells, and DC11c+ blood DC) stimulated with nonselective compound resiquimod or with selective compound I.

IT **313355-91-8**

RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (screening method for identifying compds. that selectively induce interferon alpha)

RN 313355-91-8 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:900462 CAPLUS
 DN 134:56667
 TI Preparation of sulfonamide and sulfamide substituted imidazoquinolines as
 immune response modifiers
 IN Crooks, Stephen L.; Lindstrom, Kyle J.; Merrill, Bryon A.; Rice, Michael
 J.
 PA 3M Innovative Properties Company, USA
 SO PCT Int. Appl., 111 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 7


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000076519	A1	20001221	WO 2000-US15722	20000608
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6331539	B1	20011218	US 2000-589216	20000607
	CA 2376305	AA	20001221	CA 2000-2376305	20000608
	BR 2000011433	A	20020305	BR 2000-11433	20000608
	EP 1198233	A1	20020424	EP 2000-938211	20000608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	TR 200103575	T2	20020621	TR 2001-200103575	20000608
	JP 2003501474	T2	20030114	JP 2001-502852	20000608
	EE 200100669	A	20030217	EE 2001-669	20000608
	NZ 515967	A	20031031	NZ 2000-515967	20000608
	AU 772179	B2	20040408	AU 2000-53284	20000608
	EP 1438958	A1	20040721	EP 2004-4588	20000608
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY				
	RU 2248975	C2	20050327	RU 2001-132139	20000608
	NO 2001005502	A	20020207	NO 2001-5502	20011109
	ZA 2001009854	A	20030228	ZA 2001-9854	20011129
	ZA 2001009857	A	20030228	ZA 2001-9857	20011129
	ZA 2001009861	A	20030228	ZA 2001-9861	20011129
	HR 2001000890	A1	20030831	HR 2001-890	20011129
	US 2004029877	A1	20040212	US 2001-27272	20011221
	US 6800624	B2	20041005		
	US 2004204438	A1	20041014	US 2004-826836	20040416
PRAI	US 1999-138365P	P	19990610		
	US 2000-589216	A	20000607		
	US 2000-589236	A	20000607		
	EP 2000-938205	A3	20000608		
	WO 2000-US15722	W	20000608		
	US 2001-166321	A1	20010615		

US 2001-27272
OS MARPAT 134:56667
GI

A1 20011221



I



II

AB The title compds. [I; R1 = alkylNR3SO2XR4, alkenylNR3SO2XR4 (wherein X = a bond, NR5; R3 = H, alkyl; R4 = (un)substituted aryl, heteroaryl, alkyl, etc.; R5 = H, alkyl; R4 and R5 can combine to form 3-7 membered (un)substituted heterocyclic ring); R2 = H, alkyl, aryl, etc.; R = alkyl, alkoxy, halo, CF3; n = 0-4], useful as immune response modifiers, were prepared. Thus, reacting 5-dimethylamino-1-naphthalenesulfonyl chloride with 1-(4-aminobutyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine in the presence of N,N-diisopropylethylamine in CH2Cl2 afforded the naphthalenesulfonamide II which induced interferon α and TNF α biosynthesis in human cells at 0.12 μ M and 3.33 μ M, resp. The compds. I can induce the biosynthesis of various cytokines such as interferon α and TNF α (data given), and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

IT 313355-89-4P 313355-91-8P 313355-97-4P
313355-98-5P 313356-01-3P 313356-03-5P
313356-05-7P 313356-25-1P 313356-27-3P
313356-37-5P 313356-39-7P 313356-40-0P
313356-44-4P 313356-63-7P 313356-65-9P
313356-67-1P 313356-71-7P 313356-73-9P
313356-75-1P 313356-77-3P 313356-99-9P
313357-01-6P 313357-09-4P 313357-11-8P
313357-13-0P 313357-15-2P 313357-29-8P
313357-43-6P 313357-78-7P 313357-79-8P
313357-84-5P 313357-85-6P 313357-89-0P
313357-90-3P 313357-95-8P 313357-97-0P
313357-99-2P 313358-02-0P 313358-51-9P
313358-74-6P 313359-06-7P 313359-52-3P
313359-76-1P 313359-79-4P 313359-80-7P
313359-82-9P 313359-86-3P 313359-90-9P
313359-92-1P 313359-94-3P 313359-98-7P
313360-00-8P 313360-31-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonamide and sulfamide substituted imidazoquinolines as immune response modifiers)

RN 313355-89-4 CAPLUS


CN Benzenemethanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)

10826836




RN 313355-91-8 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



RN 313355-97-4 CAPLUS


CN Methanesulfonamide, N-[4-[4-amino-2-[(4-methoxyphenyl)methyl]-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RN 313355-98-5 CAPLUS


10826836

CN 1-Butanesulfonamide, N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-
(9CI) (CA INDEX NAME)



RN 313356-01-3 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-phenyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)




RN 313356-03-5 CAPLUS

CN 1-Propanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-02-4

CMF C19 H27 N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-05-7 CAPLUS

CN 1-Octanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-04-6


CMF C24 H37 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313356-25-1 CAPLUS


CN Benzenemethanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

10826836

CM 1

CRN 313356-24-0


CMF C23 H27 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-27-3 CAPLUS

CN Ethenesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-26-2

CMF C24 H27 N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-37-5 CAPLUS

CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-36-4


CMF C17 H23 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313356-39-7 CAPLUS


CN Methanesulfonamide, N-[2-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]-1,1,1-trifluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

10826836

CM 1

CRN 313356-38-6


CMF C17 H20 F3 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-40-0 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313355-91-8

CMF C19 H27 N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-44-4 CAPLUS

CN 2-Propanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-43-3


CMF C21 H31 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313356-63-7 CAPLUS


10826836

CN Benzenemethanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313355-89-4


CMF C25 H31 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313356-65-9 CAPLUS


CN Ethenesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-64-8

CMF C26 H31 N5 O2 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-67-1 CAPLUS

CN 1-Propanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-66-0


CMF C21 H31 N5 O2 S



CM 2

10826836


CRN 76-05-1
CMF C2 H F3 O2



RN 313356-71-7 CAPLUS
CN Methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-1,1,1-trifluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 313356-70-6
CMF C19 H24 F3 N5 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 313356-73-9 CAPLUS
CN 1-Propanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

10826836

CM 1

CRN 313356-72-8


CMF C17 H27 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-75-1 CAPLUS

CN 2-Propanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-74-0

CMF C17 H27 N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313356-77-3 CAPLUS

CN 1-Octanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-76-2


CMF C22 H37 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313356-99-9 CAPLUS

CN Benzenemethanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-


10826836

c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313356-98-8


CMF C21 H27 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313357-01-6 CAPLUS


CN Ethenesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-2-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-00-5

CMF C22 H27 N5 O2 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313357-09-4 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-08-3

CMF C15 H23 N5 O2 S




CM 2

CRN 76-05-1

10826836


CMF C2 H F3 O2



RN 313357-11-8 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-7,7-dimethyl-2-oxo-, (1S,4R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 313357-10-7
CMF C28 H39 N5 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




10826836

RN 313357-13-0 CAPLUS
CN 1-Butanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-12-9


CMF C22 H33 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313357-15-2 CAPLUS
CN 1-Hexadecanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-14-1

CMF C34 H57 N5 O2 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313357-29-8 CAPLUS

CN 1-Propanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-3-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-28-7


CMF C21 H30 Cl N5 O2 S



CM 2

10826836


CRN 76-05-1
CMF C2 H F3 O2



RN 313357-43-6 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[4-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-7,7-dimethyl-2-oxo-, (1R,4S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 313357-42-5
CMF C28 H39 N5 O3 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2

10826836



RN 313357-78-7 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 313357-79-8 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-78-7

CMF C16 H21 N5 O3 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10826836



RN 313357-84-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 313357-85-6 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-84-5

CMF C18 H25 N5 O3 S




CM 2

CRN 76-05-1


10826836

CMF C2 H F3 O2



RN 313357-89-0 CAPLUS

CN Benzenemethanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 313357-90-3 CAPLUS

CN Benzenemethanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-89-0

CMF C24 H29 N5 O3 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313357-95-8 CAPLUS

CN Ethanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-94-7


CMF C19 H27 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313357-97-0 CAPLUS


CN 1-Propanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

10826836

CM 1

CRN 313357-96-9


CMF C20 H29 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313357-99-2 CAPLUS


CN 1-Butanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313357-98-1

CMF C21 H31 N5 O3 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313358-02-0 CAPLUS

CN 1-Propanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-3-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313358-01-9

CMF C20 H28 Cl N5 O3 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313358-51-9 CAPLUS

CN Benzenemethanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-2-nitro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313358-50-8

CMF C24 H28 N6 O5 S




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10826836



RN 313358-74-6 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-7,7-dimethyl-2-oxo-, (1S,4R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 313358-73-5
CMF C27 H37 N5 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 313359-06-7 CAPLUS


10826836

CN 1-Octanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-05-6


CMF C25 H39 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313359-52-3 CAPLUS


CN 1-Dodecanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-51-2

CMF C29 H47 N5 O3 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313359-76-1 CAPLUS


CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[4-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-7,7-dimethyl-2-oxo-, (1R,4S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-75-0

CMF C27 H37 N5 O4 S


10826836



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 313359-79-4 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]- (9CI) (CA INDEX NAME)



10826836


RN 313359-80-7 CAPLUS

CN Methanesulfonamide, N-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-79-4


CMF C19 H31 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313359-82-9 CAPLUS


CN 2-Propanesulfonamide, N-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI). (CA INDEX NAME)

CM 1

CRN 313359-81-8

CMF C21 H35 N5 O2 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313359-86-3 CAPLUS

CN Benzenemethanesulfonamide, N-[4-(4-amino-2-butyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-85-2

CMF C25 H35 N5 O2 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313359-90-9 CAPLUS

CN Ethanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-89-6


CMF C19 H31 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313359-92-1 CAPLUS

CN 1-Propanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-


10826836

1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-91-0


CMF C20 H33 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 313359-94-3 CAPLUS


CN 1-Butanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-93-2

CMF C21 H35 N5 O3 S


10826836



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313359-98-7 CAPLUS

CN Benzenemethanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-97-6

CMF C24 H33 N5 O3 S




10826836

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 313360-00-8 CAPLUS

CN Bicyclo[2.2.1]heptane-1-methanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-7,7-dimethyl-2-oxo-, (1S,4R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 313359-99-8

CMF C27 H41 N5 O4 S




CM 2


CRN 76-05-1

CMF C2 H F3 O2

10826836



RN 313360-31-5 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-6,7,8,9-tetrahydro-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (9CI) (CA INDEX NAME)



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT